Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of $1.90, $1.82 better than the analyst estimate of $0.08. Revenue for the quarter came in at $158.57 million versus the consensus estimate of $27.66 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.